In line with the ESC mission, newly presented content is made available to all for a limited time (4 months for ESC Congress, 3 months for other ESC organised congresses). ESC Professional Members, Association Members (Ivory & above) benefit from year-round access to the resources of their respective Association, and to all content from previous editions of these congresses. Fellows of the ESC (FESC), and Professionals in training or under 40 years old, who subscribed to a Young Combined Membership package benefit from access to all ESC 365 content from all congresses, all editions, all year long. Find out more about ESC Memberships here.
Association of endothelial NO-synthase gene polymorphism with the left ventricle diastolic dysfunction and pulmonary hypertension in patients with heart failure and preserved ejection fraction
KI Cherniaieva1
,
KM Amosova1
,
YV Rudenko1
,
GV Mostbauer1
,
AB Bezrodny1
,
OI Nishkumay1
,
PO Lazarev1
,
OI Rokyta1
,
NV Bereza1
,
NV Shyshkina1
,
KP Lazareva1
,
OV Vasylenko1
,
YA Kovtun1
,
DS Sichinava1
,
ZV Lysak2
,
1National O.O. Bohomolets Medical University, Department Internal Medicine - Kiev - Ukraine
,
2Alexander Hospital of Kiev, Department of cardiac rehabilitation - Kiev - Ukraine
,
Citation:
Introduction. Pulmonary hypertension (PH) develops in 50-80% of patients with left-sided heart failure (HF), regardless to the left ventricle (LV) ejection fraction (EF). Endothelial NO-synthase (eNOS) activity plays important role in the development of PH in patients (pts) with heart failure with preserved ejection fraction (HFpEF). Genetic polymorphisms of eNOS may affect the severity of the left ventricle (LV) diastolic dysfunction (DD) and the elastic properties of systemic arteries in pts with HFpEF.
Purpose. To determine the polymorphism of the eNOS gene 786T>C rs 2070744 and the association of the corresponding genotypes with the severity of LV DD, PH and elastic properties of the arteries in patients with arterial hypertension (AH) and HFpEF.
Methods. We included 69 hemodynamically stable pts with AH and HFpEF (58.1% men, 67.4 ± 10.2 years; NYHA II-III). All patients underwent NT – proBNP evaluation; echocardiography; applanation tonometry; 6-minute walk test (6MWT); endothelium-dependent, flow-mediated vasodilation (FMD); LV myocardium mass index (LVMI), arterial elastance (Ea), ventricular elastance (Ees), their ratio (Ea/Es) and systemic arterial complaence (SAC) were also calculated. Genotyping for eNOS 3 was performed by polymerase chain reaction in the real-time. Genomic DNA samples were isolated from stabilized blood. Patients were divided into 3 groups, according to genotype.
Results. "Wild" homozygous TT genotype was found in 34 (49.3%) pts (TT group), heterozygous TC genotype – in 21 (30.4%) pts (TC group), "mutant" homozygous CC genotype – in 14 (20.3%) pts (CC group). Pts did not differ in gender (19 (55.9%), 12 (60%), 11 (61.1%) men, respectively), age (67.1 ± 8.9, 65.4 ± 10.6, 64.9 ± 10.3 years, respectively), and the prevalence of comorbidities (all p> 0.05). In pts of CC group, compared with TT and TC, there was the worst result of 6MWT (314.3 ± 69.1, 371.8 ± 77.7, 385.7 ± 85.4 m, respectively); higher NT-proBNP level (806.9 ± 369.7, 668.1 ± 317.8, 636.9 ± 433.2 pg/ml, respectively); greater LVMI (187.4 ± 37.1, 182.2 ± 25.7, 195.2 ± 28.5 g/m2 respectively); more pronounced LV DD, according to average e' (4.7 ± 0.6, 5 ± 1.7, 5.3 ± 0.8 sm/sec, respectively) and E/e' ratio (15.9 ± 2.1, 14.5 ± 1.3, 15.1 ± 1.5, respectively); the highest systolic pulmonary artery pressure (50 ± 19.9; 39.6 ± 10.3; 40 ± 19.2 mmHg, respectively); worse elastic properties of arteries according to augmentation index (33,8±4,9, 26,5±4,6, 27,3±5,6%, respectively), pulse wave velocity (13,1±0,7, 12,2±0,8, 12,4±1,1 sm/sec, respectively), SAC (1,1±0,2, 1,6±0,2, 1,55±0,3 ml/mmHg, respectively), Ea (2,3±0,2, 1,9±0,3, 2,1±0,3, respectively) and worse results of the FMD (8,1±2,5,10,1±4,5, 9,8±2,2, respectively, (all p <0.05).
Conclusions. Compared to other polymorphisms, the CC genotype of the NOS3 rs 2070744 gene is associated with more impaired LV diastolic function and systemic arteries elasticity, and greater PH in patients with AH and HFpEF.
ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.
Our mission: To reduce the burden of cardiovascular disease